A Step-by-Step Guide to IVDR Class B Implementation, Documentation and Conformity Assessment


Common Challenges in IVDR Class B Compliance and How Manufacturers Can Address Them


Moving an in vitro diagnostic medical device into the European market requires more than developing a technically functional product. Manufacturers must also demonstrate that the device satisfies the requirements of Regulation (EU) 2017/746. For companies working with Class B diagnostic devices, the conformity assessment process introduces additional responsibilities involving notified body review, quality management systems, technical documentation and performance evaluation.


Many manufacturers already have established quality processes and product testing records under previous regulatory arrangements. However, transitioning to the IVDR can reveal gaps in documentation, performance evidence and regulatory traceability. These challenges are particularly important for businesses that previously relied on self-declaration under the former In Vitro Diagnostic Medical Devices Directive. Under the IVDR, Class B devices require notified body involvement, meaning that manufacturers must develop a more structured approach to demonstrating conformity.


The IVDR Class B service page at i3cglobal.com/ivdr-class-b/ discusses several important compliance areas, including notified body assessment, technical documentation, quality management and performance evidence. Understanding common difficulties in these areas can help manufacturers plan their regulatory activities and avoid preventable complications.



Challenge 1: Incorrect or Incomplete Device Classification


One of the earliest challenges involves determining whether a product belongs to Class A, B, C or D. Classification is based on the intended purpose and applicable rules in Annex VIII of the IVDR. It should not be determined solely by the manufacturer's preferred regulatory route or the classification assigned to a similar product by another company.


Errors at this stage can affect the entire compliance strategy. A manufacturer that incorrectly identifies a Class B device may prepare an unsuitable technical documentation package or misunderstand the need for notified body assessment. Classification decisions should therefore be supported by a documented regulatory rationale.



Practical Solution: Develop a Classification Assessment


Manufacturers should prepare an intended-purpose statement that clearly identifies the target analyte, specimen type, intended user, target population and medical purpose. The applicable Annex VIII rules should then be reviewed against the product's characteristics. Where a product family contains several devices, the classification should be evaluated for each relevant device rather than automatically assuming that all products belong to the same category.



Challenge 2: Incomplete Technical Documentation


Technical documentation is one of the most demanding elements of IVDR compliance. Annex II requires manufacturers to provide detailed information about the device, its design, manufacturing processes, performance, safety and regulatory conformity. Annex III addresses post-market surveillance documentation.


Manufacturers sometimes assume that existing product specifications, manufacturing instructions and laboratory reports are sufficient. However, notified body assessment requires evidence that is organised, traceable and directly connected to the applicable regulatory requirements. Missing validation reports, inconsistent device descriptions or unsupported performance claims can result in additional assessment questions.



Practical Solution: Use a Structured Technical File


A technical documentation structure should be established before submission. Each document should have an identifiable purpose and a clear relationship with the relevant regulatory requirement. Companies should maintain controlled versions and ensure that the information in the technical file matches the product label, instructions for use and manufacturing records.



  • Maintain an accurate device description and intended-purpose statement.

  • Document the applicable GSPRs and methods used to demonstrate conformity.

  • Include design verification and manufacturing validation evidence.

  • Maintain risk management records and benefit-risk analysis.

  • Prepare performance evaluation documentation.

  • Include relevant stability, usability and software information.

  • Maintain appropriate post-market surveillance documentation.



Challenge 3: Demonstrating Analytical and Clinical Performance


Performance evidence is central to the IVDR because diagnostic results can influence medical investigations and patient management. Manufacturers must establish scientific validity, analytical performance and clinical performance as applicable to the device's intended purpose.


A common difficulty is relying on a limited number of analytical studies without adequately explaining how the results support the product's intended use. For example, a reagent may produce consistent measurements under controlled conditions, but manufacturers must also consider whether its performance remains suitable across relevant specimen types, interfering substances and operating conditions.



Practical Solution: Create a Performance Evaluation Strategy


Manufacturers should establish a performance evaluation plan that identifies the evidence required for each performance element. Analytical studies should be selected according to the characteristics of the device. Scientific validity should be supported by appropriate scientific information, while clinical performance should be evaluated using evidence relevant to the intended population and clinical application.


Where existing evidence is used, its relevance, reliability and limitations should be explained. Any identified evidence gaps should be addressed through additional studies or a scientifically justified approach where permitted by the applicable regulatory requirements.



Challenge 4: Quality Management System Gaps


An established quality management system is necessary for maintaining regulatory compliance throughout the product lifecycle. EN ISO 13485:2016 provides a commonly used framework for medical device quality management. However, simply possessing an ISO certificate does not prove that every IVDR requirement has been fulfilled.


Problems can arise when procedures do not adequately address regulatory changes, supplier controls, design changes, traceability, complaint investigations or post-market surveillance. In some organisations, departments maintain separate records without a consistent document control process. This can make it difficult to demonstrate that the quality system supports the device's actual manufacturing and regulatory activities.



Practical Solution: Perform a QMS Gap Assessment


A detailed gap assessment should compare existing procedures against applicable IVDR requirements and the manufacturer's responsibilities. Particular attention should be given to design controls, risk management, supplier qualification, manufacturing validation, nonconformity management, corrective and preventive actions and post-market processes.



Challenge 5: Understanding Notified Body Assessment


Class B devices require notified body involvement, and manufacturers must prepare for the applicable conformity assessment route. Annex IX involves quality management system assessment and technical documentation assessment, while Annex XI provides a production quality assurance approach. The manufacturer must determine the appropriate route and understand the documentation and assessment activities involved.


Another challenge is the assessment of representative devices within a device category. Manufacturers should not assume that a notified body will review only one technical file and automatically extend the assessment to every product in a broad portfolio. Device categorisation and representative selection require a suitable regulatory rationale and complete supporting documentation.


Companies should prepare clear product-family descriptions and explain the similarities and differences between devices. This can help establish a more transparent assessment structure.



Challenge 6: Managing IVDD to IVDR Transition Requirements


Some products previously self-declared under the IVDD have moved into a classification that requires notified body involvement under the IVDR. Eligible legacy devices may benefit from the transitional provisions introduced through amendments to the regulation, provided that the relevant eligibility conditions are fulfilled.


For eligible Class B legacy devices, the extended transition period can allow continued market placement until 31 December 2029, subject to applicable conditions. These include upgrading the quality management system to meet IVDR requirements by 26 May 2025, lodging a notified body application by 26 May 2027 and signing a formal written agreement with the notified body by 26 September 2027. Other applicable conditions must also be satisfied.


Manufacturers should verify eligibility carefully and maintain documentary evidence supporting their transitional status. Transition provisions should not be interpreted as a general exemption from IVDR compliance.



Why Professional Regulatory Guidance Can Be Valuable


Regulatory consulting can help organisations understand complex requirements and organise compliance activities. I3CGLOBAL presents its IVDR Class B services as combined regulatory and product technical consultation. Manufacturers can explore its service information to understand the support areas relevant to their regulatory preparation.


When evaluating consulting support, companies should clarify deliverables, documentation responsibilities, technical expertise and the scope of assistance with notified body preparation. The manufacturer remains responsible for ensuring that the device complies with applicable regulatory requirements.



Building a More Reliable Compliance Process


A practical compliance programme should include clearly assigned responsibilities, realistic project milestones and regular documentation reviews. Instead of preparing the entire technical file immediately before a notified body submission, manufacturers should develop the documentation alongside product development and quality management activities.



  • Conduct a regulatory gap assessment at the beginning of the project.

  • Confirm product classification and intended purpose.

  • Establish a device-specific performance evaluation plan.

  • Update QMS procedures and maintain implementation records.

  • Prepare technical documentation using controlled templates.

  • Review all labels and instructions for use for consistency.

  • Establish post-market surveillance and vigilance procedures.

  • Monitor applicable regulatory developments and transition conditions.



Conclusion


IVDR Class B compliance involves several interconnected responsibilities, and manufacturers can encounter difficulties when classification, technical documentation, performance evaluation and quality management are handled independently. Addressing these challenges through a structured regulatory strategy can improve documentation consistency and assessment readiness.

A proactive approach is particularly important for manufacturers transitioning from IVDR Class B Devices IVDD requirements or preparing their first notified body IVDR Class B Devices application. With appropriate technical preparation and regulatory guidance, businesses can build a more sustainable compliance system. I3CGLOBAL provides information about its IVDR Class B consulting and technical support services for organisations seeking assistance with this process.

Leave a Reply

Your email address will not be published. Required fields are marked *